Spyre Therapeutics (SYRE) stock is reacting to fresh clinical updates after the company completed enrollment in all sub studies of its SKYWAY Phase 2 trial of SPY072 in multiple rheumatic disease indications.

At a share price of $80.79, Spyre Therapeutics has seen strong momentum recently, with a 7 day share price return of 9.7%, a 90 day share price return of 83.3% and a year to date share price return of 164.2%. The 1 year total shareholder return of very roughly 3.7x and 3 year total shareholder return of more than 22x point to a stock where enthusiasm around the pipeline is already well reflected in past performance.

If you are looking beyond Spyre to other healthcare opportunities, this could be a good moment to scan companies linked to similar themes using our screener for 40 healthcare AI stocks

With the share price already up sharply and Spyre valued at roughly US$7b despite zero revenue and a recent net loss of US$148.7m, the key question is whether there is still a buying opportunity or if the market is already pricing in future growth.

Preferred Price to Book Multiple of 13.6x: Is It Justified?

Spyre Therapeutics trades on a P/B of 13.6x, which is well ahead of both its biotech peers and the broader US Biotechs industry at the latest close of $80.79.

The P/B ratio compares the stock price to the company’s book value per share. A higher multiple usually reflects strong market expectations relative to the current balance sheet. For a clinical stage biotech with no revenue and a recent net loss of $148.7m, a high P/B typically signals that investors are placing significant value on the pipeline and future optionality rather than current financials.

Compared to the US Biotechs industry average of 2.4x, Spyre’s 13.6x P/B is considerably higher, and it is also above the peer average of 12x. That gap suggests the market is pricing Spyre at a premium to both its immediate peer group and the wider sector based on expectations that are already more optimistic than the average biotech story.

Result: Price-to-book of 13.6x (OVERVALUED)

However, this optimism still faces clear risks, including the company’s zero revenue today and its recent net loss of US$148.7m at a roughly US$7b valuation.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

Given how upbeat the story around Spyre already sounds, this is a good time to pressure test the thesis yourself and consider acting promptly. Start by reviewing the company's 4 important warning signs

Looking for more investment ideas?

Do not stop with one stock. Broaden your watchlist now so you are not chasing opportunities after they have already moved.

• Target potential bargains by filtering for quality companies trading on attractive valuations using the 44 high quality undervalued stocks.
• Prioritize resilience by focusing on businesses with strong finances through the solid balance sheet and fundamentals stocks screener (48 results).
• Search for future standouts before the crowd notices by checking the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.